11:12 AM EST, 01/13/2025 (MT Newswires) -- (Updates with Eli Lilly's ( LLY ) response in the fifth paragraph.)

Eli Lilly ( LLY ) filed lawsuits against two medical spas, Thrive Health and Wellness and Valhalla Vitality, accusing them of selling unapproved drugs claiming to contain tirzepatide, the active ingredient in its weight-loss medication Zepbound, Reuters reported Monday.

Lilly alleges that both companies are making false claims about their products' efficacy, purity, and safety, according to the report.

Thrive Health promotes its compounded drug, "MEGALean - Premium Tirzepatide Injections," as clinically tested for weight loss and blood sugar management, Reuters said, adding Valhalla Vitality similarly advertises its version of tirzepatide as safe and effective for weight loss.

The complaint against Thrive was filed in Colorado, while the case against Valhalla was lodged in the Eastern District of New York, according to Reuters.

"Lilly filed two lawsuits against entities that put patients at risk by deceiving them about the safety, clinical testing, and effectiveness of their compounded knockoff tirzepatide products," a company spokesperson told MT Newswires in an e-mailed statement. "One defendant sold knockoff tirzepatide contaminated with potentially deadly bacteria. The other deceptively marketed its untested knockoff tirzepatide as clinically tested and proven to facilitate weight loss and improve blood sugar."

Thrive Health and Valhalla Vitality did not immediately respond to MT Newswires' requests for comment.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 787.93, Change: -11.97, Percent Change: -1.50